Loading
NASDAQHealthcareBiotechnology
Latest quote
$1.10
−$0.06 · -5.17%
Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical evaluation for its effectiveness in addressing organ dysfunction and failure that arises from sepsis. Additionally, Allocetra is being investigated in preclinical studies for its potential application in solid tumor therapy.
Previous close
$1.10
−$0.06 · -5.17%
Regular session · ET · Market data may be delayed.
Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical evaluation for its effectiveness in addressing organ dysfunction and failure that arises from sepsis. Additionally, Allocetra is being investigated in preclinical studies for its potential application in solid tumor therapy.
Day range
Current $1.10
52-week range
Current $1.10
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
71
Undervalued
Sentiment
38
Bearish
Risk
73
High Risk
Momentum
20
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical evaluation for its effectiveness in addressing organ dysfunction and failure that arises from sepsis. Additionally, Allocetra is being investigated in preclinical studies for its potential application in solid tumor therapy.
Day range
Current $1.10
52-week range
Current $1.10
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 332K USD | 545K USD | 835K USD | 777K USD | 546K USD |
| Gross profit | −332K USD | −545K USD | −835K USD | −777K USD | −546K USD |
| Research and development | 8.92M USD | 10.13M USD | 19.24M USD | 18.69M USD | 12.88M USD |
| Selling, general, and administrative | 5.69M USD | 4.91M USD | 6.14M USD | 6.7M USD | 6.24M USD |
| Operating expenses | 14.67M USD | 14.99M USD | 29.4M USD | 25.8M USD | 19.29M USD |
| Interest income | 792K USD | 1.07M USD | 1.57M USD | 835K USD | 120K USD |
| Interest expense | 13K USD | 13K USD | 14K USD | 5.26M USD | 328K USD |
| Depreciation and amortization | 332K USD | 545K USD | 835K USD | 777K USD | 546K USD |
| Operating income | −15M USD | −15.54M USD | −29.4M USD | −25.8M USD | −19.29M USD |
| Net income | 1.24B USD | −15.01M USD | −29.07M USD | −31.06M USD | −14.47M USD |
Company facts updated Sep 8, 2026.
Recent quarterly results
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
